Objective This study evaluated the effect of peripheral lymphocyte count on 2 interferon-gamma release assays [QuantiFERON TB-Gold (QFT-G) and enzyme-linked immunospot (ELISPOT)] and their sensitivity in patients with pulmonary tuberculosis, including HIV-negative immunocompromised patients. Patients and Methods Two hundred thirty patients with microbiologically confirmed active pulmonary tuberculosis were subjected to the tests. Lymphocyte counts were analyzed simultaneously. Results Overall sensitivity was 74% (159/215; 95% CI, 68-80%) for [89][90][91][92][93][94][95][96] for ELISPOT (p<0.0001). In patients with peripheral lymphocyte counts of !1000/μL, sensitivity was high for both QFT-G (88%, 111/126; 82-94%) and ELISPOT (97%, 122/126; 94-100%). However, the sensitivity decreased significantly with decreasing peripheral lymphocyte count for both QFT-G (test for trend p< 0.0001) and ELISPOT (test for trend p=0.007). When lymphocyte counts were <500/μL, the sensitivity was 81% (25/31; 66-96%) for ELISPOT, but only 39% (12/31; 21-57%) for QFT-G. Conclusion Both QFT-G and ELISPOT are sensitive methods for detecting active pulmonary tuberculosis, but their sensitivity partly depends on peripheral lymphocyte counts. At low lymphocyte count conditions, ELISPOT is superior to QFT-G for detecting tuberculosis, irrespective of age, gender, and nutrition.
Introduction
Until recently, the detection of latent Mycobacterium tuberculosis infection (LTBI) was only based on tuberculin skin testing (TST). With the advent of highly specific interferon-gamma (IFN-γ) release assays (IGRAs), however, alternatives are now available. False-positive results with TST occur because of antigenic cross-reactivity of the purified protein derivative with non-M. tuberculosis infections, including those caused by Bacille Calmette-Guerin (BCG) vaccination. In contrast, IGRAs are not affected by BCG vaccination and most non-M. tuberculosis infections, and are at least as sensitive as TST for detecting active tuberculosis (1, 2) . Therefore, the Centre for Disease Control and Prevention (CDC) guideline recommends that IGRAs are more useful than TST for detection of LTBI (3, 4) .
Although the overall sensitivity of IGRAs such as QuantiFERON TB Gold (QFT-G) and enzyme-linked immunospot (ELISPOT) were reported to be very high, these were evaluated only in studies that excluded distinctly immunocompromised patients (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . However, immunocompromised hosts, including elderly and patients receiving immunosuppressive agents, have a greater risk of tuberculosis than usual hosts. Some studies on immunocompromised hosts have reported that IGRAs are more useful than TST, but the sensitivity of IGRAs was diminished in those patients (1, (6) (7) (8) (9) . It has also been reported that CD4 lympho-cyte counts affect the positive and intermediate responses of [10] [11] [12] [13] [14] [15] .
Therefore, this study was conducted to quantify the effect of peripheral blood lymphocyte count on QFT-G and ELIS-POT and to evaluate their sensitivity in patients with pulmonary tuberculosis, including HIV-negative immunocompromised patients.
Methods

Setting, patient recruitment, and eligibility
In total, 602 patients who were clinically suspected of pulmonary tuberculosis infection were tested with QFT-G and ELISPOT simultaneously, between January 2008 and June 2009 at the Department of Pulmonary Medicine, Tokyo National Hospital, National Health Organization (Tokyo, Japan). Patients provided written and informed consent. Two hundred and fifteen HIV-negative patients with M. tuberculosis infection confirmed by positive culture and/or PCR for M. tuberculosis from sputum or bronchoalveolar lavage were recruited prospectively. Patients were tested before or within 14 days of initiation of chemotherapy. Information on immunosuppressive therapy, malignancies, and bedridden status was collected from each patient at the time of enrollment. Laboratory findings [peripheral blood cell count, lymphocyte count, serum albumin (Alb), C-reactive protein (CRP), and haemoglobin A1c (HbA1c)], sputum smear status, and radiological findings were obtained at the same time.
QFT-G and ELISPOT were performed by the following procedures. Furthermore, the sensitivity of each assay was calculated and the results were analysed according to peripheral lymphocyte counts. We compared the mean peripheral lymphocyte counts between groups with positive, negative, and indeterminate results of the 2 IGRAs.
Furthermore, univariate and multivariate analyses were performed with respect to the significant contributing factors for the results of the sensitivity of these assays in detecting pulmonary tuberculosis.
This study was approved by the ethics committee of Tokyo National Hospital, National Health Organization (Tokyo, Japan).
QFT-G test
The QFT-G test was performed according to the recommendations of the manufacturer (Cellestis, Ltd., Carnegie, Victoria, Australia), and the test results were evaluated according to the guidelines of CDC (21) .
ELISPOT assays
Peripheral blood mononuclear cells were separated from the heparinized blood sample by density centrifugation using BD Vacutainer Cell Preparation Tubes (Becton, Dickinson and Company, Franklin Lakes, NJ). We seeded pre-coated IFN-γ ELISPOT plates (BD) with 2.5×10 5 cells per well in AIM-V medium (GIBCO), and then incubated with ESAT-6 (5 g/mL) and CFP-10 (5 g/mL) peptides at 37 in 5% carbon dioxide for 16 h. A negative control (no mitogen or antigen) and a positive control (phytohemagglutinin, 5 g/mL) were included. After incubation, the wells were washed and developed with a conjugate against the antibody used and an enzyme substrate. Spot-forming units were counted using a KS ELISPOT system. The results of ELISPOT were also interpreted according to the following criteria: The test result is positive if 1) the negative control has 0-5 spots and (ESAT-6 or CFP-10 spot count) (negative control spot count) 6, and/or 2) if the negative control has 6-10 spots and (ESAT-6 or CFP-10 spot count) 2× (negative control spot count). The test result is negative if the above criteria are not met and the positive control is valid. If the positive control is indeterminate (<20 spots) and both antigens are negative, the test result is regarded as indeterminate.
Statistical analysis
Data were entered using PASW statistics 17.0 for Windows and analyzed. Analyses were 2-sided, confidence intervals (CI) were 95%, and results were considered significant when p<0.05. Continuous variables were tested for normality using the Shapiro-Wilk test and compared using Student's t-test distribution. In other cases, the Mann-Whitney test and Kruskal-Wallis test were used. The chi-square test was applied for comparing categorical variables unless 1 of the categories had less than 20 observations, in which case, the Fisher's exact test was applied. A chi-square test and a linear trend test were conducted for testing trends. Odds ratio analysis for risk factors was performed by both univariate and multivariate analyses.
Results
Patient characteristics and IGRA results
Two hundred and thirty patients were examined in the study. Demographic and clinical characteristics of the study patients are summarized in Table 1 . Two hundred and thirteen were Japanese in origin, and the others were either Chinese or Filipino. A total of 215 were HIV negative. The primary diseases of the 18 patients who were undergoing immunosuppressive treatment were rheumatoid arthritis (7 patients), idiopathic interstitial pneumonia (4), microscopic polyangitis (2), sarcoidosis (1), autoimmune hepatitis (1), aplastic anaemia (1), Crohn disease (1), and Still disease (1) .
Overall sensitivity is shown Table 2 . Figure 1 and 2 show the distribution of results of ELISPOT according to the QFT-G result and vice versa, respectively. Among the 3 subgroups of 160 (74%) positive, 49 (23%) negative, and 6 (3%) indeterminate QFT-G result subjects, the median peripheral lymphocyte count was highest in the positive group Patient characteristics in various subgroups were as follows. Of 6 patients with indeterminate QFT-G results, 2 had malignancies, 1 of which was a terminal status of gastric cancer. Among the 16 with negative results for both QFT-G and ELISPOT, 5 (31%) were receiving immunosuppressive therapy, 6 (38%) were bedridden (1 of whom was also receiving immunosuppressive therapy), and 1 had a malignancy. Among the 33 patients with negative results for QFT-G and positive results for ELISPOT, 2 (6%) were receiving immunosuppressive therapy, 9 (27%) were bedridden, and 2 (6%) had malignancies. All patients with positive QFT-G results were also ELISPOT-positive. Of the 160 patients with positive results on both assays, 11 (7%) were receiving immunosuppressive therapy, 22 (14%) were bedridden (1 of whom was also receiving immunosuppressive therapy), and 1 had a malignancy (and was also bedridden).
T a b l e 1 . S u mme r y De mo g r a p h i c a n d Cl i n i c a l Ch a r a c t e r i s t i c s o f S u b j e c t s
T a b l e 2 . QF T -G a n d E L I S P OT Re s u l t s f o r Al l S t u d y P a r t i c i p a n t s
Influence of lymphocyte count on performance of QFT-G and ELISPOT analyses
When the peripheral lymphocyte count was !1,000/μL, the sensitivity of both tests was high: QFT-G (88%, 114/ 129; 95% CI, 82-94%) and ELISPOT (97%, 125/129; 95% CI, 94-100%). However, a clear trend of decreasing sensitivity with decreasing peripheral lymphocyte count was evident for both QFT-G (test for trend p<0.0001) and ELISPOT (test for trend p=0.007). This decline was more notable for QFT-G than for ELISPOT. ELISPOT was 81% (25/31; 95% CI, 66-96%) sensitive even when the lymphocyte count was less than 500/μL, whereas QFT-G was less than 70% sensitive when the lymphocyte count was <1,000/μL and less than 39% (12/31; 95% CI, 21-57%) when the lymphocyte count was <500/μL (Fig. 3) .
For further analysis of factors affecting sensitivity, QFT-G and ELISPOT results were transformed to binary variables by combining negative and indeterminate results after logistic regression analysis. In order to increase statistical power, continuous variables were redefined as dichotomous variables using the following cut-off values: age 67 years (arbitrary), serum Alb 3.3 g/dL and CRP 4.72 mg/dL (median of study population), lymphocyte count 1,000 cells/μL (definition of lymphocytopenia), and HbA1c 6.5% (recommended by the American Diabetes Association). Odds ratios for factors affecting positive QFT-G results are listed in Table 3 . The following factors were associated with a positive QFT-G result: lymphocyte count greater than 1,000 cells/μL (by both univariate and multivariate analyses), serum Alb greater than 3.3 g/dL (by both univariate and multivariate analyses), CRP greater than 4.72 mg/dL (by univariate analysis only), and bedridden status (by univariate analysis only). On the other hand, odds ratios for factors affecting positive ELIS-POT results are listed in Table 4 . Factors associated with a positive ELISPOT result were a lymphocyte count of greater than 1,000 cells/μL (by both univariate and multivariate analyses), immunosuppressive therapy (by both univariate and multivariate analyses), and serum Alb of greater than 3.3 g/dL (by univariate analysis only). 
F i g u r e 1 . Di s t r i b u t i o n o f E L I S P OT r e s u l t s , a c c o r d i n g t o r e s u l t s o b t a i n e d wi t h QF T -G. * P -v a l u e s i n d i c a t e t h e d i f f e r e n c e b e t we e n p o s i t i v e , n e g a t i v e a n d i n d e t e r mi n a t e r e s u l t s f o r QF T -G, f o r Kr u s k a l -Wa l l i s e x a c t t e s t .
F i g u r e 2 . Di s t r i b u t i o n o f QF T -G r e s u l t s , a c c o r d i n g t o r e s u l t s o b t a i n e d wi t h E L I S P OT . * P -v a l u e s i n d i c a t e t h e d i f f e r e n c e b e t we e n p o s i t i v e a n d n e g a t i v e r e s u l t s f o r E L I S P OT , f o r Ma n n -Wh i t n e y e xa c t t e s t .
Discussion
This is the first study that directs comparison of the sensitivity of 2 IGRA tests, QFT-G and ELISPOT, for detecting microbiologically determined pulmonary tuberculosis in patients, including HIV-negative immunocompromised hosts. We found that the sensitivity for the diagnosis of pulmonary tuberculosis is very high in both tests, and the sensitivity was not significantly confounded by age and gender. ELIS-POT sensitivity, but not QFT-G sensitivity, was unaffected by nutritional state as indicated by the serum Alb levels.
This study evaluated the effect of peripheral blood lymphocyte count on QFT-G and ELISPOT and their sensitivity in patients with pulmonary tuberculosis, including immunocompromised hosts. The sensitivity of both tests was affected by lymphocyte counts, with a clear trend of a decrease in sensitivity with decreasing lymphocyte count. This was particularly marked in the case of QFT-G.
Overall sensitivity determined by this study was nearly identical to the results of the meta-analysis by Pai et al (5), which reported sensitivities of 78% for QFT-G and 90% for ELISPOT but appeared inconsistent with other reports (2, 5, 17, 18, 22, 23) in suggesting that ELISPOT is significantly more sensitive than QFT-G. The correlation between peripheral lymphocyte count and the sensitivity of IGRAs has been reported previously in HIV-positive patients. In some earlier reports, QFT-G sensitivity correlated with CD 4 lymphocyte counts (8, 10, 11, 15, 24) but ELISPOT sensitivity was independent of it (19, 20, 25, 26) . In this study, ELISPOT was more than 80% sensitive even when the lymphocyte count was less than 500/μL, whereas QFT-G was less than 70% sensitive when the lymphocyte count was <1,000/μL and less than 39% when the lymphocyte count was <500/μL. In addition, nearly identical tendencies were found in a population of HIV-negative immunocompromised patients.
The present study also indicated that the group of patients with negative and indeterminate results with QFT-G had a lower mean peripheral lymphocyte count, lower than the group with positive results. Previously, HIV-positive patients with a positive QFT-G result were shown to have a significantly higher median CD4 lymphocyte count than those with a negative QFT-G (8, 11) . Moreover, as the CD4 lymphocyte counts decreased, the number of indeterminate results increased (8, 10, 11) . Our study also showed that patients with indeterminate QFT-G results had a significantly lower median peripheral lymphocyte count than those with determinate QFT-G results, and patients with negative results had a lower median peripheral lymphocyte count than patients with positive results with both QFT-G and ELIS-POT. Considering patient characteristics, 5 of 6 patients with indeterminate QFT-G results had lymphocyte counts of less than 500/μL. Two of 6 with indeterminate QFT-G results had malignancies, and 1 of these had a terminal gastric cancer. Three of the 4 remaining patients (75%) had low serum Alb levels of 1.8, 2.0, and 2.0 g/dL, despite not having any particular underlying disease. Jones et al (27) reported that the severe tubercular infections were associated with a low volume of serum Alb and CD4 lymphocyte counts in a study that measured CD4 lymphocyte counts of HIVnegative patients. Serum Alb was found to significantly affect the QFT-G sensitivity in the multivariate analysis of the study of Jones et al. However, the effect was not as remarkable as that of the lymphocyte count. This finding suggested that not only malnutrition but also advanced tuberculosis was a factor for indeterminate results (27) (28) (29) . In contrast, 1 patient had an indeterminate result, despite having a lymphocyte count of 1,640/μL. Although this patient was a 54-year-old male with no underlying disease, he had giant cavities in bilateral lung fields. In advanced tuberculosis with giant cavities, the disease state itself may control lymphocyte function, increasing the expected risk of false negative findings (3, 27, (30) (31) (32) . Therefore, these factors may have influenced the indeterminate result.
F i g u r e 3 . I n f l u e n c e o f l y mp h o c y t e c o u n t o n p e r f o r ma n c e o f t h e QF T -G a n d E L I S P OT a n a l y s i s i n p u l mo n a r y t u b e r c u r o s i s p a t i e n t s . F o r a l l p a t i e n t s t h e % o f p o s i t i v e , n e g a t i v e a n d i n d e t e r mi n a t e wa s g r o u p e d b y t h e i n d i v i d u a l n u mb e r o f l y mp h o c y t e c o u n t c e l l s / μ L . p -v a l u e s a r e f o r c h i -s q u a r e e x a c t f o r l i n e a r t r e n d . T h e n u mb e r o f p a t i e n t s i n e a c h l y mp h o c y t e c o u n t g r o u p wa
T a b l e 3 . As s o c i a t i o n o f Ri s k F a c t o r s wi t h a P o s i t i v e QF T -G Re s u l t s
T a b l e 4 . As s o c i a t i o n o f Ri s k F a c t o r s wi t h a P o s i t i v e E L I S P OT Re s u l t s
In the 16 patients with negative results for both QFT-G and ELISPOT, 5 (31%) were currently receiving immunosuppressive therapy, and their median lymphocyte count was conspicuously low (616/μL, IQR: 201, 1,776). This result confirmed that the long-term administration of glucocorticoid decreased the T lymphocyte count (33, 34) . In contrast, Matulis et al (35) reported that neither corticosteroids nor conventional DMARDs significantly affected IFN-γ responses, but the odds for a positive IFN-γ assay decreased in patients treated with TNFα inhibitors. In the 33 patients, immunosuppressive therapy subjects constituted a smaller proportion among the group with negative results for QFT-G and positive results for ELISPOT than among the group with negative results for both assays. Moreover, all QFT-Gpositive patients were positive for ELISPOT. There were few immunocompromised hosts in these subjects.
Thus, this study has indicated that the sensitivity of 2 IGRAs, QFT-G and ELISPOT, has the tendency to correlate with the peripheral lymphocyte count. This is not contradictory to the study by Ariga et al, who also found that sensitivity of QFT-G was influenced by the peripheral lymphocyte count in HIV-negative patients (Ariga et al in preparation). However, in some cases, the results of IGRAs were negative, although lymphocyte counts were not low. In multivariate analysis, the lymphocyte counts and serum Alb significantly affected QFT-G sensitivity, while lymphocyte counts and immunosuppressive therapy affected ELISPOT sensitivity. Based on the above, lymphocyte count alone does not affect the sensitivity of IGRAs and the IFN-γ production ability of lymphocytes may be a contributing factor. The IFN-γ production ability of lymphocytes could be measured in the positive control, and thus future research is expected.
This study also indicates that for maximum sensitivity, ELISPOT is preferred to QFT-G. The difference of sensitivity between ELISPOT and QFT-G is based on the difference in the testing principle (3) . A reliable method of detecting LTBI is required for implementing this therapy. Measures that could be taken to improve the performance of IGRAs include re-evaluation of the recommended cut-off (36) for each geographic region and exploration of alternative biomarkers for tuberculosis diagnosis.
Conclusion
The sensitivity of 2 IGRAs, QFT-G and ELIPSPOT, is partly dependent on peripheral lymphocyte counts. With low lymphocyte counts, the clinically acceptable sensitivity was better maintained with ELISPOT than QFT-G. Since the ELISPOT sensitivity is not affected by age, gender, and the nutritional state, ELISPOT is superior to QFT-G for detecting active tuberculosis in HIV-negative immunocompromised patients.
